ArticleEuropean journal of internal medicine2022
Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection.
Noah Shopen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.